These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19855161)

  • 41. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 42. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type.
    Li D; Wang C; Yao Y; Chen L; Liu G; Zhang R; Liu Q; Shi FD; Hao J
    FASEB J; 2016 Oct; 30(10):3388-3399. PubMed ID: 27342766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
    Cao J; Huang W
    PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mTORC1 Prevents Preosteoblast Differentiation through the Notch Signaling Pathway.
    Huang B; Wang Y; Wang W; Chen J; Lai P; Liu Z; Yan B; Xu S; Zhang Z; Zeng C; Rong L; Liu B; Cai D; Jin D; Bai X
    PLoS Genet; 2015 Aug; 11(8):e1005426. PubMed ID: 26241748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
    Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
    Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mTOR activity under hypoxia.
    Vadysirisack DD; Ellisen LW
    Methods Mol Biol; 2012; 821():45-58. PubMed ID: 22125059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice.
    Orlova KA; Parker WE; Heuer GG; Tsai V; Yoon J; Baybis M; Fenning RS; Strauss K; Crino PB
    J Clin Invest; 2010 May; 120(5):1591-602. PubMed ID: 20424326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A high-throughput, cell-based screening method for siRNA and small molecule inhibitors of mTORC1 signaling using the In Cell Western technique.
    Hoffman GR; Moerke NJ; Hsia M; Shamu CE; Blenis J
    Assay Drug Dev Technol; 2010 Apr; 8(2):186-99. PubMed ID: 20085456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A FAK-PI-3K-mTOR axis is required for Wnt-Myc driven intestinal regeneration and tumorigenesis.
    Morton JP; Myant KB; Sansom OJ
    Cell Cycle; 2011 Jan; 10(2):173-5. PubMed ID: 21228625
    [No Abstract]   [Full Text] [Related]  

  • 53. Activation of mTORC1 signaling pathway in AIDS-related lymphomas.
    El-Salem M; Raghunath PN; Marzec M; Liu X; Kasprzycka M; Robertson E; Wasik MA
    Am J Pathol; 2009 Aug; 175(2):817-24. PubMed ID: 19608873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The integral role of mTOR in lipid metabolism.
    Soliman GA
    Cell Cycle; 2011 Mar; 10(6):861-2. PubMed ID: 21325894
    [No Abstract]   [Full Text] [Related]  

  • 55. mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death.
    Leibowitz BJ; Zhao G; Xia W; Wang Y; Ruan H; Zhang L; Yu J
    Oncogene; 2023 Jun; 42(24):2007-2016. PubMed ID: 37138032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the appropriateness of antibody selection to estimate mTORC1 activity.
    Figueiredo VC; Dungan CM; Peterson CA; McCarthy JJ
    Acta Physiol (Oxf); 2020 Feb; 228(2):e13354. PubMed ID: 31365789
    [No Abstract]   [Full Text] [Related]  

  • 57. mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer.
    Afzal O; Altamimi ASA; Mubeen B; Alzarea SI; Almalki WH; Al-Qahtani SD; Atiya EM; Al-Abbasi FA; Ali F; Ullah I; Nadeem MS; Kazmi I
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Translation initiation and its relevance in colorectal cancer.
    Minnee E; Faller WJ
    FEBS J; 2021 Dec; 288(23):6635-6651. PubMed ID: 33382175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucocorticoids Promote the Onset of Acute Experimental Colitis and Cancer by Upregulating mTOR Signaling in Intestinal Epithelial Cells.
    Zhang Z; Dong L; Jia A; Chen X; Yang Q; Wang Y; Wang Y; Liu R; Cao Y; He Y; Bi Y; Liu G
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevation of n-3/n-6 PUFAs ratio suppresses mTORC1 and prevents colorectal carcinogenesis associated with APC mutation.
    Liu M; Zhou L; Zhang B; He M; Dong X; Lin X; Jia C; Bai X; Dai Y; Su Y; Zou Z; Zheng H
    Oncotarget; 2016 Nov; 7(47):76944-76954. PubMed ID: 27769066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.